Table 1.

Modes of antiviral interference exemplifying the codetermination of viral replication efficiency by viral and host-specific factors.

	vCDK/pUL97	CDK7	Cyclin H
Impact on HCMV replication	antiviral drug: EC50 maribavir 0.35 ± 0.42 µM (Wild et al., 2022)	antiviral drug: EC50 LDC4297 0.009 ± 0.002 µM (Wild et al., 2022)	transient cyclin H KO: % HCMV vs. control cells AD169: 60.9 ± 0.5 * (Schütz et al., 2022) inducible cyclin H KD: % HCMV vs. control cells AD169: 19.9 ± 5.5* Merlin WT 6.0 ± 1.2* Merlin ORF-UL97 A594V 9.4 ± 0.4* (present study)

^⁎HCMV replication efficiency in HFF KO/KD cells compared to control cells. Primary values of viral genome equivalents obtained from the replication kinetics (i.e. last day transient cyclin H KO AD169 7 d p.i., last day inducible cyclin H KD AD169 16 d pi., last day inducible cyclin H KD Merlin WT/A594V 17 d p.i) were divided by the respective genomic values obtained at 2 d p.i. and finally normalized using their control values (i.e. HFFs WT or non-induced cells).